EX-99.1 2 ldr-20150515ex9913bb87b.htm EX-99.1 Exhibit 991 FY15 Q2 Earnings Press Release

News Release

 

LANDAUER

 

 

 

LANDAUER, INC. Reports

Fiscal 2015 SECOND QUARTER RESULTS

 

 

For Further Information Contact:

Jim Polson

FTI Consulting

Phone: 312-553-6730

Email: jim.polson@fticonsulting.com

 

 

GLENWOOD, Ill.— May 11, 2015—Landauer, Inc. (NYSE: LDR), a recognized leader in personal and environmental radiation measurement and monitoring, outsourced medical physics services and high quality medical consumable accessories, today reported financial results for its fiscal 2015 second quarter ended March 31, 2015.

 

Fiscal 2015 Second Quarter Highlights

·

Revenue of $38.1 million, a 2.6% decrease compared to the year ago period

o

Second quarter domestic Radiation Measurement revenues grew 4.3% year-over-year

o

Second quarter Medical Physics revenues grew 7.5% year-over-year

o

Unfavorable foreign currency rates reduced revenues by $1.6 million, or 4.1% year-over-year

·

Operating income of $5.6 million, a decrease of 18.8% over the prior year period

o

Professional fees, primarily associated with the fiscal 2014 Form 10-K restatement and accounting control issues, reduced operating income by $1.1 million year-over-year

·

Net Income of $3.5 million, compared to $4.5 million in the prior year period

·

Adjusted EBITDA of $9.0 million, a decrease of $2.4 million from the prior year period

 

Mike Leatherman, President and Chief Executive Officer of Landauer stated, “While our reported results for the second quarter reflected the impact of foreign currency and our audit, legal and professional fees incurred to complete our latest Form 10-K filing, our core business remains strong. During the quarter, revenues in our domestic radiation measurement segment grew 4.3%, and revenues in our Medical Physics segment grew 7.5%.  The growth in these services demonstrates the strength of our unique position as an integrated solution for our customers.” 

 

Leatherman continued, “During the second quarter, we have continued to focus on our strategic priorities that will drive long-term, profitable growth, including the continued progress of our next generation digital dosimeter platform, Verifii, and the remediation of the accounting control issues identified in our latest Form 10-K filing. We remain confident that we have put the right team and structure in place to drive growth for our shareholders.”

 

Second Fiscal Quarter Financial Overview

 

Revenues for the second fiscal quarter of 2015 were $38.1 million, a decrease of $1.0 million, or 2.6%, compared to revenues of $39.1 million for the second fiscal quarter of 2014. Radiation Measurement revenues for the second fiscal quarter of 2015 were $27.2 million, a 5.2% decrease compared to $28.7 million for the second fiscal quarter of 2014. The decrease in revenues was due primarily to the unfavorable impact of changes in foreign currency exchange rates of $1.6 million and a decrease in product sales in Europe of $1.0 million, partially offset by an increase in military product sales of $1.1 million. Medical Physics revenues increased $0.6 million, due to increased imaging services. Medical Products revenues were flat.

Operating income for the second fiscal quarter of 2015 was $5.6 million, a decrease of $1.3 million, or 18.8%, compared with operating income of $6.9 million for the second fiscal quarter of 2014. The decrease in operating income was driven by lower gross profit of $1.2 million, resulting from unfavorable foreign currency rates, and higher audit, legal, and professional fees associated with the fiscal 2014 Form 10-K restatement and accounting control issues.

 

Fiscal Six Months Financial Overview

 

Revenues for the first six months of fiscal 2015 were $75.7 million, a 1.9% decrease compared to $77.2 million for the first six months of fiscal 2014. The Radiation Measurement segment decreased $3.2 million due to an unfavorable foreign currency impact of $2.4 million and a decrease in product sales in Europe of $1.0 million, partially offset by an increase in military product sales of $0.4 million. The Medical Physics segment increased $1.3 million, driven by new customer contracts for outsourced enterprise radiation safety solutions.  Revenues in the Medical Products segment increased $0.3 million due to the full-period impact of a modest acquisition in December 2013.

 

Operating income for the first six months of fiscal 2015 was $11.8 million, a 4.1% decrease compared to operating income of $12.3 million for the first six months of fiscal 2014.  The decrease in operating income was driven by unfavorable foreign currency rates, and higher audit, legal, and professional fees associated with the fiscal 2014 Form 10-K restatement and accounting control issues.

 

Fiscal 2015 Outlook

 

Landauer’s business plan for fiscal 2015 currently anticipates aggregate revenues for the year to be in the range of $153 to $163 million. This range reflects the uncertainty of the impact of foreign currencies, and to a lesser extent, government funding during fiscal 2015 for military equipment sales opportunities.  The business plan also anticipates:

 

·

The effective tax rate for the full fiscal year is anticipated to be within a range of 21 percent to 25 percent.

·

Based upon the above assumptions, the Company anticipates Adjusted Net Income for fiscal 2015 in the range of $16 to $19 million and Adjusted EBITDA expected for fiscal 2015 in the range of $41 to $46 million.

·

Due to the impact of unfavorable foreign currency rates on reported revenues, Adjusted Net Income and Adjusted EBITDA, the Company expects to report fiscal 2015 results near the lower end of the range for these metrics.

 

Conference Call Details

 

Landauer has scheduled its second quarter conference call for investors over the Internet on Monday, May 11, 2015, at 4:00 p.m. Central Time (5 p.m. Eastern Time).  To participate, callers should dial 888-417-8533 (within the United States and Canada), or 719-325-2455 (international callers) about 10 minutes before the presentation.  To listen to a webcast on the Internet, please go to the Company’s website at http://www.landauer.com at least 15 minutes early to register, download and install any necessary audio software.  Investors may access a replay of the call by dialing 888-203-1112 (within the United States and Canada), or 719-457-0820 (international callers), passcode 8727665#, which will be available through Wednesday, June 10, 2015.  The replay will also be available on Landauer’s website for 30 days following the call.

 

About Landauer

 

Landauer is a leading global provider of technical and analytical services to determine occupational and environmental radiation exposure, the leading domestic provider of outsourced medical physics services, as well as a provider of high quality medical accessories used in radiology, radiation therapy, and image guided surgery procedures.  For more than 50 years, the Company has provided complete radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries in which radiation poses a potential threat to employees.  Landauer’s services include the manufacture of various types of radiation detection monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings.  The Company provides its dosimetry services to approximately 1.8 million individuals globally.  In addition, through its Medical Physics segment, the Company provides therapeutic and imaging physics services to the medical physics community. Through its Medical Products segment, the Company provides medical consumable accessories used in radiology, radiation therapy, and image guided surgery procedures.  For information about Landauer, please visit their website at http://www.landauer.com.

 

 

 

Safe Harbor Statement

 

Some of the information shared here (including, in particular, the section titled “Fiscal 2015 Outlook”) constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties.  These include the following, without limitation: assumptions, risks and uncertainties associated with the Company’s future performance, the Company’s development and introduction of new technologies in general; the ability to protect and utilize the Company’s intellectual property; continued customer acceptance of the InLight technology; the adaptability of optically stimulated luminescence (OSL) technology to new platforms and formats; military and other government funding for the purchase of certain of the Company’s equipment and services; the impact on sales and pricing of certain customer group purchasing arrangements; changes in spending or reimbursement for medical products or services; the costs associated with the Company’s research and business development efforts; the usefulness of older technologies and related licenses and intellectual property; the effectiveness of and costs associated with the Company’s IT platform enhancements; the anticipated results of operations of the Company and its subsidiaries or ventures; valuation of the Company’s long-lived assets or business units relative to future cash flows; changes in pricing of services and products ; changes in postal and delivery practices; the Company’s business plans; anticipated revenue and cost growth; the ability to integrate the operations of acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally; costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing economic and competitive conditions, including instability in capital markets which could impact availability of short and long-term financing; the timing and extent of changes in interest rates; the level of borrowings; foreign exchange rates; government regulations; accreditation requirements; changes in the trading market that affect the costs of obligations under the Company’s benefit plans; and pending accounting pronouncements.  These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from what is anticipated today.  These risks and uncertainties also may result in changes to the Company’s business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses.  Additional information may be obtained by reviewing the information set forth in Item 1A “Risk Factors” and Item 7A “Quantitative and Qualitative Disclosures about Market Risk” and information contained in the Company's Annual Report on Form 10-K for the year ended September 30, 2014 and other reports filed by the Company, from time to time, with the Securities and Exchange Commission.  The Company does not undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or changes in the Company’s expectations, except as required by law.

 

 

 

Financial Tables Follow 

 

 

  Landauer, Inc. and Subsidiaries 

Consolidated Balance Sheets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(Dollars in Thousands)

 

March 31,
2015

 

September 30,
2014

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$
8,424 

 

$
6,761 

Receivables, net of allowances of $1,703 at March 31, 2015 and $1,872 at September 30, 2014

 

 
30,756 

 

 
34,707 

Inventories

 

 
6,689 

 

 
6,687 

Prepaid expenses and other current assets

 

 
7,041 

 

 
6,178 

Current assets

 

 
52,910 

 

 
54,333 

Net property, plant and equipment

 

 
46,973 

 

 
46,757 

Equity in joint ventures

 

 
23,137 

 

 
23,835 

Goodwill

 

 
40,432 

 

 
43,218 

Intangible assets, net of accumulated amortization of $37,624 at March 31, 2015 and $37,579 at September 30, 2014

 

 
13,369 

 

 
14,077 

Other assets

 

 
32,136 

 

 
34,366 

Assets

 

$
208,957 

 

$
216,586 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current liabilities

 

$
39,595 

 

$
44,728 

Non-current liabilities:

 

 

 

 

 

 

Long-term debt

 

 
134,585 

 

 
133,585 

Other non-current liabilities

 

 
24,183 

 

 
24,539 

Non-current liabilities

 

 
158,768 

 

 
158,124 

Stockholders' equity:

 

 

 

 

 

 

Landauer, Inc. stockholders' equity

 

 
9,361 

 

 
12,254 

Noncontrolling interest

 

 
1,233 

 

 
1,480 

Stockholders' equity

 

 
10,594 

 

 
13,734 

Liabilities and Stockholders' Equity

 

$
208,957 

 

$
216,586 

 

 

 

 

 

Landauer, Inc. and Subsidiaries 

Second Fiscal Quarter 2015 Financial Highlights

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
March 31,

 

 

Six Months Ended
March 31,

(Dollars in Thousands, Except per Share)

 

2015

 

2014
(As Restated)

 

2015

 

2014
(As Restated)

Net revenues

 

$
38,139 

 

$
39,054 

 

$
75,686 

 

$
77,201 

Cost and expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Cost of sales

 

 
18,611 

 

 
18,332 

 

 
36,362 

 

 
36,717 

Selling, general and administrative

 

 
13,898 

 

 
13,750 

 

 
27,553 

 

 
27,976 

Acquisition, reorganization and nonrecurring costs

 

 

 -

 

 
109 

 

 

 -

 

 
220 

Costs and expenses

 

 
32,509 

 

 
32,191 

 

 
63,915 

 

 
64,913 

Operating income

 

 
5,630 

 

 
6,863 

 

 
11,771 

 

 
12,288 

Equity in income of joint ventures

 

 
680 

 

 
535 

 

 
1,376 

 

 
1,816 

Other expense, net

 

 
(1,449)

 

 
(1,009)

 

 
(2,151)

 

 
(1,787)

Income before taxes

 

 
4,861 

 

 
6,389 

 

 
10,996 

 

 
12,317 

Income tax expense

 

 
1,180 

 

 
1,913 

 

 
2,790 

 

 
3,812 

Net income

 

 
3,681 

 

 
4,476 

 

 
8,206 

 

 
8,505 

Less:  Net income (loss) attributed to noncontrolling interest

 

 
134 

 

 
(38)

 

 
282 

 

 
170 

Net income attributed to Landauer, Inc.

 

$
3,547 

 

$
4,514 

 

$
7,924 

 

$
8,335 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income per share attributable to Landauer, Inc. shareholders:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$
0.37 

 

$
0.47 

 

$
0.83 

 

$
0.87 

Weighted average basic shares outstanding

 

 
9,493 

 

 
9,460 

 

 
9,464 

 

 
9,441 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted

 

$
0.37 

 

$
0.47 

 

$
0.83 

 

$
0.87 

Weighted average diluted shares outstanding

 

 
9,520 

 

 
9,501 

 

 
9,492 

 

 
9,485 

 

 

 

Landauer, Inc. and Subsidiaries 

Consolidated Statements of Cash Flows

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended
March 31,

(Dollars in Thousands)

 

2015

 

2014
(As Restated)

Cash flows from operating activities:

 

 

 

 

 

 

Net income

 

$
8,206 

 

$
8,505 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

Depreciation and amortization

 

 
6,092 

 

 
7,487 

Equity in  income of joint ventures

 

 
(1,376)

 

 
(1,816)

Dividends from joint ventures

 

 
1,144 

 

 
1,340 

Stock-based compensation and related net tax benefits

 

 
873 

 

 
453 

Current and long-term deferred taxes, net

 

 
(1,792)

 

 
847 

Loss on sale, disposal and abandonment of fixed assets

 

 
124 

 

 

 -

Gain on investments

 

 
(189)

 

 
(338)

Changes in operating assets and liabilities

 

 
1,775 

 

 
3,402 

Net cash provided by operating activities

 

 
14,857 

 

 
19,880 

Net cash used by investing activities

 

 
(2,916)

 

 
(4,329)

Cash flows used  by financing activities:

 

 

 

 

 

 

Long-term borrowings, net

 

 
1,000 

 

 
(4,500)

Dividends paid to stockholders

 

 
(10,599)

 

 
(10,520)

Other financing activities, net

 

 
(321)

 

 
(390)

Net cash used by financing activities

 

 
(9,920)

 

 
(15,410)

Effects of foreign currency translation

 

 
(358)

 

 
109 

Net increase in cash and cash equivalents

 

 
1,663 

 

 
250 

Opening balance - cash and cash equivalents

 

 
6,761 

 

 
8,672 

Ending balance - cash and cash equivalents

 

$
8,424 

 

$
8,922 

 

 

 

A reconciliation of these non-GAAP measures to the most directly comparable GAAP measures is provided below:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
March 31,

Six Months Ended
March 31,

(Dollars in Thousands)

2015

 

2014
(As Restated)

2015

 

2014
(As Restated)

Adjusted EBITDA

 

 

 

 

 

 

 

 

 

 

Net income attributed to Landauer, Inc.

$
3,547 

 

$
4,514 

$
7,924 

 

$
8,335 

Add back:

 

 

 

 

 

 

 

 

 

 

Net financing costs

 
849 

 

 
957 

 
1,687 

 

 
1,746 

Depreciation and amortization

 
3,014 

 

 
3,755 

 
6,092 

 

 
7,487 

Provision for income taxes

 
1,180 

 

 
1,913 

 
2,790 

 

 
3,812 

Earnings before interest, taxes, depreciation
and amortization (EBITDA)

$
8,590 

 

$
11,139 

$
18,493 

 

$
21,380 

Adjustments:

 

 

 

 

 

 

 

 

 

 

Non-cash stock based compensation

 
436 

 

 
171 

 
873 

 

 
463 

Acquisition, reorganization and nonrecurring costs

 

 -

 

 
109 

 

 -

 

 
220 

Sub-total adjustments

 
436 

 

 
280 

 
873 

 

 
683 

Adjusted EBITDA

$
9,026 

 

$
11,419 

$
19,366 

 

$
22,063 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
March 31,

Six Months Ended
March 31,

(Dollars in Thousands, Except per Share)

2015

 

2014
(As Restated)

2015

 

2014
(As Restated)

Adjusted Net Income

 

 

 

 

 

 

 

 

 

 

Net income attributed to Landauer, Inc.

$
3,547 

 

$
4,514 

$
7,924 

 

$
8,335 

Sub-total adjustments

 
436 

 

 
280 

 
873 

 

 
683 

Income taxes on adjustments

 
(106)

 

 
(84)

 
(220)

 

 
(211)

Adjustments, net

 
330 

 

 
196 

 
653 

 

 
472 

Adjusted Net Income

$
3,877 

 

$
4,710 

$
8,577 

 

$
8,807 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended
March 31,

(Dollars in Thousands)

2015

 

2014
(As Restated)

Adjusted Free Cash Flow

 

 

 

 

 

Net cash provided by operating activities

$
14,857 

 

$
19,880 

Capital expenditures

 
(3,063)

 

 
(2,415)

Free Cash Flow

 
11,794 

 

 
17,465 

Acquisition, reorganization and nonrecurring costs

 

 -

 

 
220 

Adjusted Free Cash Flow

$
11,794 

 

$
17,685 

 

 

 

Segment Information

 

The following tables summarize financial information for each reportable segment for the three and six months ended March 31: 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
March 31,

 

Six Months Ended
March 31,

(Dollars in Thousands)

 

2015

 

2014
(As Restated)

 

2015

 

2014
(As Restated)

Revenues by segment:

 

 

 

 

 

 

 

 

 

 

 

 

Radiation Measurement

 

$
27,246 

 

$
28,684 

 

$
53,737 

 

$
56,867 

Medical Physics

 

 
8,561 

 

 
8,029 

 

 
17,045 

 

 
15,768 

Medical Products

 

 
2,332 

 

 
2,341 

 

 
4,904 

 

 
4,566 

Consolidated revenues

 

$
38,139 

 

$
39,054 

 

$
75,686 

 

$
77,201 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
March 31,

 

Six Months Ended
March 31,

(Dollars in Thousands)

 

2015

 

2014
(As Restated)

 

2015

 

2014
(As Restated)

Operating income (loss) by segment:

 

 

 

 

 

 

 

 

 

 

 

 

Radiation Measurement

 

$
9,414 

 

$
9,800 

 

$
18,798 

 

$
18,629 

Medical Physics

 

 
321 

 

 
599 

 

 
939 

 

 
1,032 

Medical Products

 

 
244 

 

 
(174)

 

 
578 

 

 
(462)

Corporate

 

 
(4,349)

 

 
(3,362)

 

 
(8,544)

 

 
(6,911)

Consolidated operating income

 

$
5,630 

 

$
6,863 

 

$
11,771 

 

$
12,288